What is a rare risk associated with SSRI Embryopathy concerning the newborn?

What is a rare risk associated with SSRI Embryopathy concerning the newborn?

• A. Spinal muscular atrophy
• B. Persistent pulmonary hypertension
• C. Neonatal sepsis
• D. Intrauterine growth restriction

Answer: (B)

The rare risk associated with SSRI (Selective Serotonin Reuptake Inhibitor) embryopathy concerning the newborn is persistent pulmonary hypertension of the newborn (PPHN). PPHN is a serious condition that affects the transition of blood circulation in newborns after birth. It occurs when a newborn's circulation system does not adapt properly to breathing air outside the womb, leading to higher pressure in the pulmonary arteries and inadequate oxygenation of the blood. Several studies have indicated that the use of SSRIs during pregnancy, especially in the late third trimester, is linked to an increased risk of PPHN. It is crucial to monitor infants who were exposed to SSRIs in utero for signs of this condition, as early recognition and management can significantly improve outcomes. In comparison to the other options, PPHN is recognized specifically in relation to SSRI exposure. Spinal muscular atrophy is a genetic disorder unrelated to SSRI use during pregnancy, neonatal sepsis occurs due to infections and is not directly connected to SSRIs, and intrauterine growth restriction can have various causes that are not uniquely identified with the use of SSRIs. Therefore, persistent pulmonary hypertension stands out as a significant concern specifically related to SSRI embryopathy.

The rare risk associated with SSRI (Selective Serotonin Reuptake Inhibitor) embryopathy concerning the newborn is persistent pulmonary hypertension of the newborn (PPHN). PPHN is a serious condition that affects the transition of blood circulation in newborns after birth. It occurs when a newborn's circulation system does not adapt properly to breathing air outside the womb, leading to higher pressure in the pulmonary arteries and inadequate oxygenation of the blood.

Several studies have indicated that the use of SSRIs during pregnancy, especially in the late third trimester, is linked to an increased risk of PPHN. It is crucial to monitor infants who were exposed to SSRIs in utero for signs of this condition, as early recognition and management can significantly improve outcomes.

In comparison to the other options, PPHN is recognized specifically in relation to SSRI exposure. Spinal muscular atrophy is a genetic disorder unrelated to SSRI use during pregnancy, neonatal sepsis occurs due to infections and is not directly connected to SSRIs, and intrauterine growth restriction can have various causes that are not uniquely identified with the use of SSRIs. Therefore, persistent pulmonary hypertension stands out as a significant concern specifically related to SSRI embryopathy.